Vacc-4x

BIOLOGICAL4 trials

Sponsors

Bionor Immuno AS

Conditions

HIV I InfectionHIV-1 Infection

Phase 1

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

CompletedNCT01704781

Bionor Immuno ASHIV-1 Infection

Start: 2012-09-30End: 2014-08-31Updated: 2017-03-08

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

CompletedNCT02092116

Bionor Immuno ASHIV I Infection

Start: 2014-03-31End: 2015-12-31Updated: 2017-03-01

Phase 2

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

CompletedNCT00659789

Bionor Immuno ASHIV I Infection

Start: 2008-08-31End: 2011-06-30Updated: 2017-02-23

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

CompletedNCT01712256

Bionor Immuno ASHIV-1 Infection

Start: 2012-12-31End: 2014-01-31Updated: 2017-03-06

Related Papers

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.

2016-07-07149 citations

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

2014-02-1183 citations